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ABSTRACT
Prediction of clinical efficacy, toxicity, and drug-drug interactions
may be improved by accounting for the intracellular unbound drug
concentration (Cunbound) in vitro and in vivo. Furthermore, sub-
cellular drug distribution may aid in predicting efficacy, toxicity, and
risk assessment. The present study was designed to quantify the
intracellular Cunbound and subcellular localization of drugs in rat
sandwich-cultured hepatocytes (SCH) compared with rat isolated
perfused liver (IPL) tissue. Probe drugs with distinct mechanisms of
hepatocellular uptake and accumulation were selected for in-
vestigation. Following drug treatment, SCH and IPL tissues were
homogenized and fractionated by differential centrifugation to enrich
for subcellular compartments. Binding in crude lysate and cytosol
was determined by equilibrium dialysis; the Cunbound and intracellular-
to-extracellular Cunbound ratio (Kpu,u) were used to describe accumu-
lation of unbound drug. Total accumulation (Kpobserved) in whole
tissue was well predicted by the SCH model (within 2- to 3-fold) for
the selected drugs. Ritonavir (Kpu,u ∼1) was evenly distributed among
cellular compartments, but highly bound, which explained the ob-
served accumulation within liver tissue. Rosuvastatin was recovered
primarily in the cytosolic fraction, but did not exhibit extensive
binding, resulting in a Kpu,u >1 in liver tissue and SCH, consistent with
efficient hepatic uptake. Despite extensive binding and sequestration
of furamidine within liver tissue, a significant portion of cellular accu-
mulation was attributed to unbound drug (Kpu,u >16), as expected for
a charged, hepatically derived metabolite. Data demonstrate the
utility of SCH to predict quantitatively total tissue accumulation and
elucidate mechanisms of hepatocellular drug accumulation such as
active uptake versus binding/sequestration.
Introduction
The impact of drugs on intracellular targets of efficacy and/or
toxicity, and susceptibility to elimination, is driven by local unbound
concentrations (Cunbound) according to the “free drug hypothesis”
(Smith et al., 2010). Prediction of clinical efficacy, toxicity, and drug-
drug interactions (DDIs) could be improved by accounting for
Cunbound in vitro and in vivo (Zhou et al., 2011; Zhang et al., 2012).
Furthermore, subcellular drug distribution may aid prediction and/or
correlation of efficacy and/or toxicity and risk assessment for drugs
(Reasor and Kacew, 2001; Gunawan and Kaplowitz, 2007; Labbe
et al., 2008). Measurement of blood or plasma Cunbound is convenient
and may correlate with tissue concentrations for compounds with
sufficient passive permeability. However, for hydrophilic compounds
(highly polar or ionized at physiologic pH) that rely on uptake/efflux
transporters for distribution and do not readily cross membrane
barriers, the intracellular and extracellular (blood or plasma) Cunbound
may be highly disparate.
The ratio of intracellular and extracellular Cunbound (Kpu,u) has been
used extensively in central nervous system pharmacokinetics-
pharmacodynamics to elucidate the role of blood-brain barrier
penetration and transport (Gupta et al., 2006) and to correlate in vivo
effects with in vitro potency (Hammarlund-Udenaes et al., 2008; Liu
et al., 2008). Figure 1 illustrates the concept of Kpu,u as it applies to
hepatobiliary drug disposition. Compounds that are taken up efficiently
into hepatocytes may exhibit a Kpu,u ..1 (Zhou et al., 2011; Shitara
et al., 2013). The important role of the organic anion–transporting
polypeptides (OATPs) has been recognized in recent years, highlighting
the need to elucidate the role of active uptake in the hepatic accumulation
of drugs (Giacomini et al., 2010; Shitara et al., 2013). Indeed, any situation
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concentration; Kpobserved, observed partition coefficient; Kppredicted, predicted partition coefficient; Kpu,u, ratio of intracellular and extracellular
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in which the net rate of appearance exceeds elimination under steady-state
conditions will result in a Kpu,u ..1; this includes formation of me-
tabolites, which are often polar and poorly permeable, relying on active
transport for elimination. A Kpu,u ,,1 in the liver indicates that the net
effects of elimination (efflux, metabolism) outweigh appearance in
the tissue/cellular compartment (low passive permeability and/or rate-
limited influx). The role of metabolic clearance and transporter-enzyme
interplay in complicating the prediction of intracellular concentrations in
hepatocyte systems has been emphasized (Parker and Houston, 2008;
Brown et al., 2010).
Hepatic intracellular Cunbound, Kpu,u, and subcellular localization
information has improved predictions and/or explained seemingly
discrepant pharmacokinetic-pharmacodynamic relationships with a va-
riety of endpoints involving efficacy (Dollery, 2013; Shitara et al.,
2013), toxicity (Chen et al., 2008), and drug disposition, including
transport (Kudo et al., 2007), metabolism (Obach, 1996, 1999;
Deshmukh and Harsch, 2011), and related DDIs (Yamano et al., 1999;
Chen et al., 2008; Sato et al., 2010; Pfeifer et al., 2013). Intracellular
Cunbound and subcellular localization of drugs are challenging to mea-
sure accurately, and our understanding of hepatocellular drug dispo-
sition remains rudimentary (Chu et al., 2013). A versatile and reliable
method to determine these parameters in a relevant hepatic in vitro
model would be of value to differentiate the contribution of active
uptake versus binding/sequestration as mechanisms of hepatocellular
accumulation, and to assess routes and rates of elimination (e.g.,
metabolism and biliary excretion) (Giacomini et al., 2010; Zhou et al.,
2011; Chu et al., 2013).
Isolated perfused livers (IPLs) are considered the gold standard for
studying the hepatobiliary system in isolation, without the influence of
extrahepatic components (Brouwer and Thurman, 1996). Unfortu-
nately, the IPL system has a number of drawbacks, including a limited
experimental period (#2 hours), the time- and labor-intensive nature
of the procedure, and limited applicability to nonrodent species
including humans. Sandwich-cultured hepatocytes (SCH) are a com-
mon in vitro model used to assess hepatic uptake and excretory
function, including DDIs and transporter-metabolism interplay (Swift
et al., 2010). Recapitulation of functional bile networks in SCH
provides a key advantage for predicting cellular accumulation of drugs
that are eliminated from hepatocytes via biliary excretion. Expression
of transport proteins and metabolizing enzymes in SCH may be
altered over days in culture compared with whole tissue (Li et al.,
2009; Tchaparian et al., 2011); however, the use of medium additives
can modulate expression levels to more closely mimic the in vivo
situation (Swift et al., 2010). Methods to estimate the cellular unbound
fraction (fu) and resulting Kpu,u in hepatocyte models in vitro include
the use of temperature, inhibitors, and/or pharmacokinetic modeling
(Parker and Houston, 2008; Yabe et al., 2011; Jones et al., 2012;
Shitara et al., 2013), but direct measurement of Kpu,u in SCH has not
been reported.
The objective of this work was to determine the intracellular
Cunbound and subcellular localization of drugs in SCH compared with
IPL tissue. A set of probe drugs with distinct mechanisms of hepa-
tocellular uptake and accumulation was selected for investigation.
Ritonavir inhibits drug transport and metabolism in vitro and in vivo
and accumulates in liver tissue (Denissen et al., 1997). Surprisingly,
the contribution of active transport to the cellular uptake and
accumulation of ritonavir has not been characterized definitively,
and reports of hepatic Kpu,u and intracellular Cunbound for prediction of
ritonavir DDIs are inconsistent (Parker and Houston, 2008; Griffin
et al., 2011; Mateus et al., 2013; Pfeifer et al., 2013). Rosuvastatin,
a 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitor with
a primary site of action in hepatocytes, is taken up efficiently by
OATPs and accumulates within hepatocytes, with a Kpu,u .1 (Nezasa
et al., 2002a, 2003; Yabe et al., 2011; Shitara et al., 2013). Furamidine
is formed in the liver via sequential metabolism from the prodrug
pafuramidine; furamidine is poorly permeable and must be excreted
from hepatocytes into the systemic circulation to exert antiparasitic
activity (Paine et al., 2010; Yan et al., 2011). This set of drugs
provided a useful range of tissue accumulation, hepatic fu, subcellular
distribution, and Kpu,u values for comparison of methods to determine
hepatocellular Cunbound.
Materials and Methods
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise stated. Rosuvastatin (Nezasa et al., 2002b) and the deuterated
internal standard (d6-rosuvastatin), as well as ritonavir (Denissen et al., 1997),
were purchased from Toronto Research Chemicals (Toronto, ON, Canada).
Furamidine, the prodrug pafuramidine, and internal standard (deuterium-labeled
Fig. 1. The tissue-to-plasma unbound concentration ratio (Kpu,u) applied to hepatobiliary drug disposition.
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furamdine) were synthesized in the laboratory of Dr. David W. Boykin
(Georgia State University, Atlanta, GA), as reported previously (Yan et al.,
2011).
Tissue Accumulation. Male Wistar rats (Charles River Laboratories,
Wilmington, MA) were used for IPL studies. Rats were allowed free access
to water and food and acclimated for a minimum of 1 week prior to exper-
imentation. All animal procedures complied with the guidelines of the
Institutional Animal Care and Use Committee (University of North Carolina,
Chapel Hill, NC). All procedures were performed under full anesthesia with
ketamine/xylazine (140/8 mg/kg i.p.). Livers were perfused in a single-pass
manner (30 ml/min continually oxygenated Krebs-Ringer bicarbonate buffer in
the presence of 5 mM taurocholate to maintain bile flow); following a 15-
minute equilibration period, ritonavir (1 mM) or rosuvastatin (1 mM) was
included in the perfusate for 30 minutes, and then the livers were flushed briefly
with blank buffer. Pafuramidine (10 mM) was perfused in a recirculating IPL
system with 20% blood-containing perfusate for 120 minutes as reported
previously (Yan et al., 2011). Livers were harvested and stored whole at280°C
until homogenization and analysis.
Rat hepatocytes were seeded in six-well BioCoat plates (BD Biosciences,
San Jose, CA) and overlaid with Matrigel basement membrane matrix (BD
Biosciences) in a sandwich-cultured configuration and maintained as described
previously (Swift et al., 2010). Day 4 rat SCH were preincubated for 10 minutes
in Ca2+-free Hanks’ balanced salt solution (HBSS) B-CLEAR technology;
Qualyst Transporter Solutions, Durham, NC) to open tight junctions and
prevent accumulation in bile canalicular spaces, and then treated with 1 mM
ritonavir or [3H]rosuvastatin (100 nCi/ml; American Radiolabeled Chemicals,
Inc., St. Louis, MO) for 10 minutes at 37°C as described previously (Swift
et al., 2010). Starting on day 3, pafuramidine was incubated for 24 hours at 10
mM to allow complete formation and equilibration of furamidine, as previously
reported (Yan et al., 2011), followed by a 5-minute incubation in Ca2+-free
HBSS. In all cases, incubation medium was collected at the end of the
incubation period, and cells were washed three times in ice-cold HBSS.
Fractionation. Liver tissue was homogenized in 3–5 volumes of fraction-
ation buffer [250 mM sucrose, 10 mM HEPES, 10 mM KCl, 1 mM EDTA,
1.5 mM MgCl2, 1 mM dithiothreitol, cOmplete Protease Inhibitor Cocktail
(Roche Diagnostics, Indianapolis, IN)] using a Potter-Elvehjem homogenizer.
Following treatment with the drug of interest, all wells of the six-well SCH
plate were harvested and pooled by scraping each well sequentially into 1 ml
fractionation buffer. Collected cells in buffer were homogenized by passing
10 times through a 27 gauge needle, resting 10 minutes on ice, followed by an
additional 10 passes. Following homogenization to disrupt cell membranes, the
resulting crude lysates (liver and SCH) were sampled and reserved to perform
analysis for total and unbound drug concentrations, protein content, and enzyme
activity assays. The remaining lysate was subjected to stepwise differential cen-
trifugation as published previously (Ward et al., 2000) to separate the following
cellular components: 10 minutes at 600g (nuclei and cellular debris), 10,000g
(mitochondria), and 35,000g (lysosomes and other medium-sized membrane-
bound bodies), and 60 minutes at 100,000g (microsomes, membrane fraction),
with the resulting supernatant representing the cytosolic fraction. All spins
,100,000g were repeated after resuspending the pellet in 5 (liver) or 0.2 (SCH)
ml of fractionation buffer; resulting supernatants were pooled before moving on
to subsequent centrifugation steps. Pellets were resuspended in fractionation
buffer [10 ml for liver tissue and 0.3 (600g) or 0.15 (.600g) ml for SCH] for
analysis of drug and protein content and enzyme activities.
Protein content of each fraction was determined using the Pierce BCA
Protein Assay (Thermo Fisher Scientific, Inc., Rockford, IL). Separation and
recovery of subcellular fractions were assessed by measuring lactate dehy-
drogenase (LDH) activity as a cytosolic marker using a Cytotoxicity Detection kit
(Roche Diagnostics) and acid phosphatase activity as a lysosomal marker using
an Acid Phosphatase kit (Sigma-Aldrich). Succinate dehydrogenase activity was
measured to assess the presence of mitochondria as described previously (Gong
et al., 2007), adapted to a microplate format as follows: 5 ml sample volume was
combined with 60 ml 10 mM sodium succinate in 50 mM phosphate buffer and
incubated for 60 minutes at 37°C, followed by the addition of 20 ml 2.5-mg/ml
p-iodonitrotetrazolium and incubation for another 15 minutes. The reaction was
quenched by the addition of 0.2 ml of 5:5:1 (v/v/w) ethanol/ethyl acetate/
trichloroacetic acid and absorbance was determined at 492 nm on a plate-based
spectrophotometer (BioTek PowerWave HT, Winooski, VT). Similarly, glucose
6-phosphatase activity was measured to assess the presence of microsomes as
described previously (Ockerman, 1967), adapted to a microplate format as follows:
10 ml sample volume was plated in duplicate and combined with 10 ml 20 mM
Tris-HCl, pH 7.3, with and without 50 mM glucose 6-phosphate (Na+ salt; Sigma-
Aldrich) and incubated for 30 minutes at 37°C. Inorganic phosphate standards
were prepared from 0.1–2 mM and added to the plate (20 ml) at the end of the
incubation. The reaction was terminated by the addition of 200 ml detection
reagent [3:1 1 mg/ml malachite green (oxalate salt; Sigma-Aldrich) in 1 N HCl/
4.2% (w/v) ammonium molybdate in 5 N HCl] to samples and standards, followed
immediately by the addition of 10 ml 0.05% (v/v) Tween-20. The reaction mixture
was shaken briefly and allowed to equilibrate for 10–15 minutes, and absorbance
was determined at 660 nm on a plate-based spectrophotometer. Phosphate
formation was calculated as the difference between samples incubated with and
without glucose 6-phosphate substrate to correct for endogenous phosphate content
in the samples. Recovery of each fraction was calculated as the percentage of the
total organelle-specific enzyme activity detected in each subfraction compared with
the whole lysate.
Binding. Binding was determined in whole-tissue lysates and cytosolic
fractions by equilibrium dialysis. Initial studies were performed to determine the
time to equilibrium and test for protein leakage or potential volume shifts with
whole-liver tissue (data not shown). Aliquots were loaded into a 96-well
equilibrium dialysis apparatus (HTDialysis, LLC, Gales Ferry, CT) and dialyzed
against phosphate buffer for 6 hours with shaking at 37°C. Binding replicates
(n = 3) consisted of 3-fold dilutions of each sample (1-, 3-, and 9-fold original
sample). The unbound fraction (fu) was back-extrapolated to account for dilution
during the homogenization/fractionation process, as well as subsequent dilutions,






This approach provides the best precision in the linear range, and that precision
is lost when the measured unbound fraction becomes high (fu,measured . 80%).
In cases where fu,measured was .80% at the lowest dilution, the value was
reported as “greater than” the undiluted fu, calculated according to the equation
above.
Sample Analysis. Ritonavir, rosuvastatin, and furamidine were quantified
by liquid chromatography–tandem mass spectrometry as described previously;
rosuvastatin was quantified by liquid scintillation counting for SCH studies (Abe
et al., 2008; Rezk et al., 2009; Lee and Brouwer, 2010; Yan et al., 2011). Total
cellular concentrations in SCH were calculated by dividing the quantified substrate
mass in the whole lysate by 7.4 ml/mg protein in SCH, the estimated hepatocellular
volume determined by [3H]3-O-methyl-D-glucose (Lee and Brouwer, 2010).
Data Analysis. The observed partition coefficient (Kpobserved) was calculated
as the total tissue concentration (liver or SCH) divided by the outflow perfusate
(IPL) or buffer (SCH) total concentration measured at the end of the perfusion or
incubation, respectively. The predicted partition coefficient (Kppredicted) was
calculated as the reciprocal of the tissue unbound fraction (fu,tissue), assuming 1)
no binding in the extracellular matrix (buffer; fu,extracell = 1) and 2) equilibration
between intracellular (tissue) and extracellular Cunbound (Cu,tissue = Cu,extracell):
Kppredicated ¼ Cu;tissue=fu;tissueCu;extracell=fu;extracell ¼ 1=fu;tissue ð2Þ
where the tissue unbound fraction was determined using whole lysate or cytosol
[fu,tissue = fu,lysate = (fcytosol • fu,cytosol)], and fcytosol represents the fraction of the
total drug mass residing in the tissue (whole liver or SCH) that was recovered in
the cytosol (final supernatant following fractionation): (Ccytosol • Vcytosol)/
(Clysate • Vlysate); C and V represent concentration and volume, respectively;
subscripts represent the cytosolic fraction (cytosol; final supernatant at the end
of the fractionation procedure) and the whole lysate prior to fractionation
(lysate). The unbound tissue concentration was calculated as the product of the
tissue unbound fraction determined in whole lysate or cytosol and the total
tissue concentration (Cu,tissue = fu,tissue • Ctissue),where Ctissue = Clysate • Vlysate /
Vtissue; tissue volume (Vtissue) for whole liver (IPLs) was determined
gravimetrically prior to homogenization, or calculated as 7.4 ml/mg protein
in SCH, as indicated above. The ratio of intracellular and extracellular Cunbound
(Kpu,u) was calculated as the unbound tissue concentration divided by the
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unbound concentration in perfusate or buffer (fu,buffer was assumed to be 1 in
the absence of protein in both systems).
Results
To characterize the subcellular distribution of the probe compounds,
differential centrifugation was performed on lysates from whole-liver
tissue and SCH following drug treatment. Marker enzyme activities
specific to mitochondria, lysosomes, endoplasmic reticulum (micro-
somes), and cytosol were examined in tissue lysate and subfractions to
assess the purity and recovery of the various fractions. The distribution
of these organelles in subfractions of whole-liver tissue and SCH is
shown in Fig. 2. Using whole-liver tissue, separation of subfractions
was demonstrated, with organelle-specific enzyme activity detected
largely in the expected fractions. The lysosomal marker, acid phos-
phatase, was recovered primarily in the final supernatant instead of
the 35,000g pellet, as would have been expected. Following fraction-
ation of SCH lysates, the majority of membrane-bound organelles
(including mitochondria and microsomes) were recovered in the initial
low-speed spin (600g). Cytosolic separation and recovery was efficient
and successful, as shown in Fig. 2, with ;90% of the total LDH
activity in the crude lysate recovered in the cytosolic fraction of SCH
lysates.
Recovery of the probe drugs in all fractions was compared with the
total mass in the whole lysate prior to fractionation. Recovery of probe
drugs after fractionation of whole-liver tissue and SCH was
approximately 100% (610%). The average subcellular distribution
of each drug in whole tissue and SCH is shown in Fig. 3. In all cases,
the coefficient of variation was less than 20% when at least 10% of the
drug was recovered in a given fraction. In whole-liver tissue, approx-
imately 36% of the ritonavir was found in the cytosolic fraction, 31%
in the microsomal fraction, and 18% in the mitochondrial fraction,
with the remainder distributed fairly evenly among the remaining
fractions. In SCH lysates, cytosolic recovery of ritonavir was similar
to that in whole-liver tissue (43%). The remaining ritonavir was re-
covered primarily in the initial low-speed spin, consistent with binding/
sequestration to organelles (including microsomes), which were difficult
to separate in SCH lysates. Rosuvastatin distribution was confined
primarily to the cytosol, with recovery of 72% in the cytosolic fraction
of whole-liver tissue and 88% in SCH lysates. Rosuvastatin distribution
to specific organelles was minimal (,11%). Furamidine was localized
in the mitochondrial (43%), nuclear (18%), and lysosomal (15%) frac-
tions of tissue lysate from the rat IPL; the remaining material was
recovered in the cytosolic fraction, with minimal localization in the
microsomal fraction. Furamidine was recovered predominantly (85%)
in the initial low-speed spin (600g) following fractionation of SCH
lysates, with minor recovery in the remaining fractions, including cytosol
(3%). This is consistent with extensive binding and/or sequestration
within membrane-bound organelles (including mitochondria), which
were recovered in the 600g pellet following initial centrifugation of SCH
lysates.
Concentrations of probe drugs in tissue, along with binding data and
calculated concentration ratios (Kp and Kpu,u), are listed in Table 1.
Total tissue accumulation (Kp) ranged over 3 orders of magnitude in
the compound set selected for investigation. Ritonavir binding was
extensive in whole-liver tissue and SCH (fu,lysate of 1.0% 6 0.1% and
3.0% 6 1.0%, respectively). Predicted accumulation (Kppredicted) of
ritonavir based on binding and subcellular distribution (91–100 in IPL,
22–35 in SCH) was in good agreement with observed accumulation
(Kpobserved; 110 and 33 in IPL and SCH, respectively). The estimated
intracellular Cunbound approximated the extracellular concentration, re-
sulting in a Kpu,u of ;1, suggesting that binding to cellular components
can explain the observed tissue accumulation. Rosuvastatin displayed
moderate accumulation in liver tissue and SCH (Kpobserved of 33 and 17,
respectively) in the absence of extensive binding and/or sequestration.
Kppredicted (;3–4 in IPL and SCH) underestimated the observed
accumulation, as might be expected for a compound that is a substrate
for hepatic uptake transporters. The estimated intracellular Cunbound and
resulting Kpu,u (;8–11) suggested accumulation of unbound rosuvas-
tatin within the liver. Calculation of a precise Kpu,u in SCH was
complicated by the low degree of binding in the diluted SCH lysate and
cytosolic fraction, but accumulation of unbound drug was evident based
on a Kpu,u value .5–6. Furamidine accumulation was extensive in
whole-liver tissue and SCH (Kp of 8400 and 6900, respectively).
Although furamidine also was extensively bound or sequestered,
Kppredicted underestimated the observed accumulation by more than
10-fold. The estimated intracellular Cunbound and resulting Kpu,u (.16)
confirmed accumulation of unbound drug within hepatocytes.
Discussion
The present study evaluated an organ-specific in vitro model system
to estimate Cunbound and predict cellular partitioning and accumulation
of drugs. The SCH system exhibits properly localized and functional
transport proteins as well as metabolic and regulatory machinery. This
system may be able to recapitulate the relevant cellular disposition of
drugs whose distribution is influenced by the interplay of these
processes in hepatocytes in vivo.
Total accumulation (Kpobserved) in whole tissue was well predicted
by the SCH model (within 2- to 3-fold) for the limited compound
set selected for investigation. A system that enables accurate esti-
mates of hepatic Kp values would be a valuable addition to phy-
siologically based pharmacokinetic modeling efforts to predict hepatic
exposure in humans. Although tissue partitioning can be predicted
using physicochemical properties, such as the method of Rodgers
and Rowland (Rodgers et al., 2005; Rodgers and Rowland, 2006),
exceptions and inaccuracies inevitably exist, particularly for com-
pounds that may rely on active processes, such as transport and/or
metabolism.
Although the Kp value is useful for estimating total tissue con-
centration, it does not provide information on the mechanism(s) of
tissue accumulation. For mechanistic information, one must assess
tissue binding and subcellular distribution. Kpu,u is an informative
parameter for describing the potential role of active uptake; however,
a Kpu,u 1 does not necessarily imply that passive processes (e.g.,
diffusion) are solely responsible for hepatocellular distribution.
Although it is tempting to dismiss the potential contribution of active
transport for such compounds, it is possible that a net balance exists
between uptake and efflux processes. In such a case, impaired
transport function (e.g., DDIs, genetic variation, and/or disease) may
result in altered hepatic and/or systemic exposure, with corresponding
implications for changes in efficacy, toxicity, and DDI potential. For
example, while the Kpu,u of ritonavir in the current study was ;1,
ritonavir is excreted into bile in rats, dogs, and humans (Denissen
et al., 1997; Pfeifer et al., 2013) and inhibits P-glycoprotein- and
multidrug resistance–associated protein (MRP)-mediated efflux in
vitro (Gutmann et al., 1999; Vourvahis and Kashuba, 2007). Although
the role of hepatic uptake in ritonavir disposition has not been reported
conclusively, uptake into suspended hepatocytes is sensitive to
temperature (Parker and Houston, 2008), and ritonavir is a competitive
inhibitor of OATP-mediated uptake (Annaert et al., 2010). Ritonavir
accumulation (Kp) and Kpu,u (;600 and ;10, respectively) in
suspended hepatocytes (Parker and Houston, 2008; Yabe et al., 2011)
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was greater than total accumulation reported in whole liver [10- to
100-fold in vivo (Denissen et al., 1997) and ;50 in the present study]
and the Kpu,u of ;1 in SCH and IPLs in the present study. This
discrepancy is likely due, at least in part, to internalization of the
canalicular membrane in suspended hepatocytes, rendering biliary
excretion nonfunctional (Bow et al., 2008), and underscores the
importance of using a model that recapitulates the totality of liver
function as closely as possible. Interestingly, the Kp of ;100 and Kpu,u
of 1.7 reported recently for ritonavir in human embryonic kidney (HEK)
293 cells were in excellent agreement with the present studies in whole
rat liver and SCH, despite the fact that HEK293 cells largely lack the
assortment of transporters and metabolizing enzymes expected to
influence the hepatocellular disposition of drugs (Mateus et al., 2013).
We demonstrated recently that ritonavir did not inhibit MRP2-mediated
biliary excretion of the imaging agent 99mTc-mebrofenin in humans
(Pfeifer et al., 2013). This apparent in vitro–in vivo disconnect was
reconciled by accounting for the Cunbound of ritonavir in hepatocytes
relative to its inhibitory potency against MRP2 (Pfeifer et al., 2013), and
Fig. 2. Distribution and recovery of organelle-specific marker enzyme activity following differential centrifugation of whole-liver tissue (A) and SCH (B). Data are
expressed as % total activity in the initial lysate recovered in each pellet; mean 6 S.D. of n = 3 (whole liver) or n = 9 (SCH). (See Materials and Methods for more details.)
super, supernatant.
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highlights the importance of estimating accurately the relevant hepa-
tocellular Cunbound to predict potential DDIs.
Rosuvastatin accumulation in whole liver (Kpobserved = 33) and SCH
(Kpobserved = 17) was in good agreement with previous reports of 18-
to 45-fold hepatic accumulation after oral administration in rats
(Nezasa et al., 2002b) and 15-fold accumulation in isolated hepa-
tocytes (Nezasa et al., 2003). Although rosuvastatin binding did
account for a portion of tissue accumulation (Kppredicted ;3–4), the
majority of accumulation was due to unbound drug (Kpu,u of 8–11),
consistent with efficient hepatic uptake and rate-limited efflux, and
previous Kpu,u values ranging from ;10–60 in vitro (Nezasa et al.,
2003; Yabe et al., 2011; Shitara et al., 2013). Rosuvastatin binding
data in SCH demonstrated a limitation associated with the required
dilution of small in vitro tissue samples when performing these
studies. For compounds such as rosuvastatin that are not extensively
bound (fu,measured . 80%), dilution of SCH samples upon collection
resulted in observed binding data that were difficult to extrapolate
accurately. Therefore, the resulting Kpu,u value in SCH is a conservative
minimum and potentially underestimates the true value. However, the
observed SCH fu,lysate of .36% 6 3% is similar to the 48% reported
previously in suspended hepatocytes (Yabe et al., 2011), so the reported
Kpu,u of .5–6 from SCH (Table 1) is likely less than a 2-fold
underestimate, and still indicates the contribution of active uptake.
Extensive hepatic accumulation of the active metabolite, furami-
dine, was observed in both rat IPLs and SCH, as reported previously
(Yan et al., 2011). Previous studies using differential centrifugation
revealed that furamidine was localized primarily in the mitochondrial
fraction of the liver and kidney (Midgley et al., 2007). Similarly,
furamidine was localized primarily in the mitochondrial fraction
(43%) following subcellular fractionation of tissue lysate from the rat
IPL. Despite extensive binding and sequestration, these processes
underpredict the observed accumulation in liver tissue. Accumulation
of unbound furamidine (Kpu,u) was predicted to be $16-fold,
suggesting permeability-limited efflux of this charged metabolite
formed in the hepatocyte. The extensive hepatic binding/sequestration
may limit the systemic exposure to furamidine; in contrast, a structural
analog had a 5-fold greater hepatic fu, which could contribute, in part,
to the enhanced systemic exposure of this agent compared with
furamidine (Yan et al., 2011).
Subcellular fractionation has not been reported in SCH. An estab-
lished method to determine subcellular localization and sequestration
of drugs and/or metabolites in a relevant in vitro system would be
useful. This is particularly true of the liver, where drug-induced liver
injury via idiosyncratic hepatocellular injury is the most frequent
cause of regulatory action on drugs, including failure to approve,
labeling changes, and withdrawal from the market (Watkins et al.,
2008). Hepatotoxic drugs are known to cause hepatocellular injury
through diverse pathways, including organelle-specific sequestration
and toxicity, such as phopholipidosis (lysosomes) (Reasor and Kacew,
2001) and mitochondrial disruption/dysfunction (Labbe et al., 2008),
among others (Gunawan and Kaplowitz, 2007). Although isolation of
subcellular fractions consisting of membrane-bound organelles proved
challenging in SCH, cell lysis, with release and isolation of soluble
cytosolic proteins and contents, was successful as determined by LDH
activity and rosuvastatin recovery. Enzyme markers of subcellular
Fig. 3. Subcellular distribution and recovery of ritonavir, rosuvastatin, and
furamidine following differential centrifugation of whole-liver tissue (IPL) and
SCH. Data are presented as % recovery of total drug in lysate. Open bars, 600g
pellet; light gray, 10,000g pellet; cross-hatch, 35,000g pellet; diagonal hash,
100,000g pellet; black, 100,000g supernatant. (See Materials and Methods for more
details.)
TABLE 1




IPL SCH IPL SCH IPL SCH
Ctissue (mM) 56 15 6 2 18 17 6 3 24
c 1500 6 500
Cmedium (mM) 0.49 0.47 6 0.12 0.54 1 0.0032
c,d 0.27 6 0.19
Kpobserved 110 33 33 17 8400
c,d 6900
Whole lysatea
fu,lysate (%) 1.0 6 0.1 3.0 6 1.0 23 6 1 .36 6 3
b 0.3 6 0.1c 0.9 6 0.2
Kppredicted 100 35 4.3 ,2.8 330 110
Cu,tissue (mM) 0.56 0.46 6 0.16 4.1 .6.1 0.073 14 6 6
Kpu,u 1.1 1.1 7.9 .6.1 23 53
Cytosola
fcytosol (%) 36 43 6 8 72 88 6 1 20 3 6 1
fu,cytosol (%) 3.3 6 0.2 11 6 1 46 6 8 .34 6 3
b 6.2 6 1.2c 11 6 4
Kppredicted 91 22 3.3 ,3.4 81 330
Cu,tissue (mM) 0.62 0.76 6 0.31 5.9 .5.0 0.30 4.3 6 1.6
Kpu,u 1.3 1.7 11 .5.0 93 16
aKppredicted and Cu,tissue calculated for lysate and cytosol as described in Materials and Methods.
bUndiluted fu and subsequent calculations represented by inequalities when fu,measured . 80%, as described in Materials and Methods.
cFrom Yan et al., 2011.
dTaking into account fu of 44% in perfusate, containing 20% whole blood, as determined by Yan et al., 2011.
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components were recovered primarily in the initial, low-speed
centrifugation step from SCH lysates, indicating that these organelles
were retained in large, dense conglomerates. It is possible that the
collagen matrix, indispensible to the sandwich configuration, pre-
vented the plasma membrane from separating enough to release larger,
membrane-bound bodies. This limitation may provide an advantage
for rapid isolation of the cytosolic fraction in SCH. The present data
suggest that a single, low-speed (600g) spin, which can be performed
on any benchtop microcentrifuge, will reliably exclude cellular organ-
elles from the resulting supernatant of SCH lysate. This single-step
method has the additional advantage of minimizing potential redis-
tribution of drugs during multiple centrifugation steps and associated
dilutions. Although the specific site(s) of subcellular sequestration
would remain unknown, extensive distribution/recovery of drug in the
pellet could indicate the need to consider intracellular pharmacoki-
netics. Meanwhile, the cytosolic fraction would contain the unbound
drug content in the tissue (fcytosol), which could be evaluated further by
determining the extent of binding to cytosolic protein (fu,cytosol), as
reported in the present studies.
A number of potential limitations are associated with the subcellular
fractionation approach, including the following. 1) There is some
degree of cross-contamination among isolated cellular fractions. This
can be assessed primarily by recovery of marker enzyme activity
specific for each organelle, but adds significant time- and labor-
intensive efforts to sample analysis. The recovery of acid phosphatase
activity in multiple fractions (Fig. 2A) is an example of potential
cross-contamination. Lysosomes are quite fragile, a characteristic that
is noted and/or exploited in traditional fractionation methods (Burn-
side and Schneider, 1982; Ohsumi et al., 1983); therefore, it is
likely that a portion of the lysosomes were disrupted during the
homogenization process in both SCH and whole-tissue matrices. 2)
Potential disruption of binding equilibrium between cellular compart-
ments occurs during the fractionation process. Tissue homogenization
and fractionation inherently involve dilution, which can shift binding
equilibrium. Despite the potential limitations of the reported method,
assessment of intracellular Cunbound and mechanisms of hepatic ac-
cumulation is challenging, and in vitro methods are needed for general
application to compounds that are not amenable to visualization by
imaging techniques such as fluorescence. Other methods are not
without limitations, such as assessment of cellular accumulation at 4°
C versus 37°C (Shitara et al., 2013). The assumption of the latter
method is that all active processes are inert at 4°C and that cellular
accumulation represents passive equilibration of unbound drug. How-
ever, the effect of temperature and potential artifacts on nonspecific
binding (Igari et al., 1981; Kodama et al., 1999; Zeitlinger et al.,
2011) and membrane fluidity and partitioning (Herbette et al., 1983;
Palmeira and Oliveira, 1992; Liu et al., 2001) are well established. The
methods applied to rat SCH in the present investigation to determine
intracellular Cunbound and Kpu,u were reported recently in immortalized
(HEK293) cells (Mateus et al., 2013), which lack the full complement
of mechanisms present in hepatocytes that influence cellular accu-
mulation (e.g., active uptake, metabolism, and biliary excretion).
Hepatic intracellular Cunbound, Kpu,u, and subcellular localization
can be used to improve prediction of clinical efficacy, toxicity, and
DDIs. A straightforward in vitro method was developed to determine
hepatocellular accumulation of total and unbound drug in the SCH
model. This method was used successfully to differentiate the contri-
bution of active transport versus binding/sequestration as mechanisms
of hepatocellular accumulation for a set of probe drugs with distinct
mechanisms of hepatocellular uptake and accumulation. Further val-
idation of this approach using SCH to determine the hepatocellular
Cunbound and Kpu,u of additional compounds is ongoing.
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